Celiac Disease Clinical Trial
Official title:
Dietary Assessment and Mycotoxin Exposure in Celiac Subjects
Celiac disease (CD) is the most common autoimmune enteropathy in Western Countries. Gluten free diet is the only available therapy but few is known about its nutrient content and mycotoxin exposure.
Celiac disease (CD) is the most common autoimmune enteropathy in Western Countries,
occurring in genetically susceptible individuals, elicited by the gluten ingestion. By
definition the disease responds to gluten withdrawal, so currently gluten free (GFD) diet is
the therapy for celiac patients. It is known that gluten rich products are important source
of nutrients on the other hands it is not clear if gluten exclusion from the diet could have
a negative effect on the nutritional status of CD patients.
Another concern related to the GFD could be the high exposure to mycotoxins due to the high
concentration of maize in GF products.
AIM The aim of this study is to estimate the nutrient intake and the dietary exposure of all
mycotoxin types in a group of treated celiac patients vs. non-celiac subjects.
METHODS We will enroll celiac patients and healthy controls. Exclusion criteria for celiac
patients will be: 1) diagnosis of CD less than two years 2) age under 18 or over 70 3)
associated metabolic or chronic disease 4) pregnancy or lactation 5) being vegetarian or
vegan. Exclusion criteria for the healthy subjects will be the same with the exception of
the diagnosis of CD.
Total food and beverage consumption will be assessed by means of a 7 days long
questionnaire. All participants will be trained by a nutritionist to record all food
consumed and the completed forms will be returned and reviewed during a face-to-face
interview at which portions size were quantified in standard units. Participants will be
asked to weigh all foods and drinks consumed and to provide a detailed description of each
food, including methods of preparation and recipes, whenever possible. In case of Gluten
Free Foods, patients will be asked to precisely note the name of the manufacturer or to
provide the food label.
The nutrient intake was calculated using a software application linked to the food database
of the European Institute of Oncology integrated with the nutrient composition of 60
commercial GF foods. The computer output will consist in the evaluation of the mean daily
intake of macro nutrients for each subject, in terms of carbohydrates, protein and lipid.
Food items consumed will be also collapsed into food categories; pasta, bread, potatoes,
flours, different cereals, fruit, vegetables, milk, cheese, eggs, fish, oils and fats,
biscuits, sweet snacks, breakfast cereals, candies, chocolate, soft drinks, juices, coffees,
teas, alcoholic beverages. For each subject, the mean daily intake of each food category
will be calculated.
The 24-h urines were collected at the end of the registration period and analyzed for
mycotoxins.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04349904 -
Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
|
||
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT05810441 -
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
|
||
Recruiting |
NCT05555446 -
Bovine Colostrum to Prevent Absorption of Gluten
|
Early Phase 1 | |
Completed |
NCT02754609 -
Hookworm Therapy for Coeliac Disease
|
Phase 1 | |
Terminated |
NCT01902368 -
Celiac Disease Screening
|
N/A | |
Completed |
NCT02472704 -
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
|
N/A | |
Completed |
NCT02312349 -
Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
|
||
Completed |
NCT01172665 -
Celiac Disease Database
|
||
Completed |
NCT01100099 -
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00639444 -
Risk of Celiac Disease and Age at Gluten Introduction
|
N/A | |
Active, not recruiting |
NCT05425446 -
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
|
Phase 1 | |
Enrolling by invitation |
NCT02202681 -
Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
|
N/A | |
Completed |
NCT00362856 -
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
|
Phase 2 | |
Terminated |
NCT03866538 -
Budesonide in Patients With Immune Mediated Enteropathies
|
Phase 4 | |
Recruiting |
NCT05135923 -
Glutenfree, Gut Microbiota and Metabolic Regulation
|
N/A | |
Completed |
NCT05052164 -
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
|
N/A | |
Completed |
NCT03775499 -
Probiotic BL NCC 2705 and Gluten Sensitivity
|
N/A | |
Completed |
NCT03707730 -
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
|
Phase 2 |